Deals supported by Xplico

  • pharmamar

Deal supported by Xplico

October, 2016|0 Comments

PharmaMar and Boryung Pharm sign a licensing agreement for Aplidin® (plitidepsin) in Korea.

  • nuevolution

Deal supported by Xplico

October, 2016|0 Comments

Nuevolution Announces Strategic Collaboration with Amgen in Oncology and Neuroscience.

  • summit

Deal supported by Xplico

October, 2016|0 Comments

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for […]

  • tracon

Deal supported by Xplico

October, 2016|0 Comments

TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson […]

  • 4sc

Spin-out supported by Xplico

September, 2016|0 Comments

4SC sells immunology portfolio to Immunic

  • leo

Deal supported by Xplico

July, 2016|0 Comments

LEO Pharma enters biologics through strategic partnership with AstraZeneca.

  • affirid

Funding round supported by Xplico

June, 2016|0 Comments

AFFiRiS AG successfully raises €10m equity financing

  • tagovax

Acquisition supported by Xplico

June, 2016|0 Comments

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology.

  • 4sc

Deal supported by Xplico

May, 2016|0 Comments

4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China.

  • pharmamar

Deal supported by Xplico

February, 2016|0 Comments

PharmaMar and Specialised Therapeutics Asia sign licensing and marketing agreement for APLIDIN® (plitidepsin) covering several Asian countries.

  • symphogen

Deal supported by Xplico

January, 2016|0 Comments

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology.

  • bavarian

Deal supported by Xplico

December, 2015|0 Comments

Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.

  • leo

Deal supported by Xplico

November, 2015|0 Comments

LEO Pharma to acquire global dermatology portfolio from Astellas.

  • obseva

Deal supported by Xplico

November, 2015|0 Comments

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis.

  • lexicon

Deal supported by Xplico

November, 2015|0 Comments

Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes.

  • nuevolution

Deal supported by Xplico

October, 2015|0 Comments

Nuevolution Announces Drug Discovery Collaboration with Johnson & Johnson Innovation.

  • pharmamar

Deal supported by Xplico

August, 2015|0 Comments

PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for
APLIDIN® (plitidepsin) in oncology.

  • inovio

Deal supported by Xplico

August, 2015|0 Comments

Inovio Pharmaceuticals enters into Strategic Cancer Vaccine Collaboration and License Agreement with MedImmune

  • pharmamar

Deal supported by Xplico

July, 2015|0 Comments

PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers

  • leo

Deal supported by Xplico

June, 2015|0 Comments

LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions

  • leo

Deal supported by Xplico

May, 2015|0 Comments

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

  • HRA

Deal supported by Xplico

April, 2015|0 Comments

HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction

  • 4sc

Deal supported by Xplico

April, 2015|0 Comments

4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan

  • medivir

Deal supported by Xplico

April, 2015|0 Comments

Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

  • immunocore

Deal supported by Xplico

April, 2015|0 Comments

Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies

  • uniqure

Deal supported by Xplico

April, 2015|0 Comments

Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases

  • bavarian

Deal supported by Xplico

March, 2015|0 Comments

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy

  • curis

Deal supported by Xplico

January, 2015|0 Comments

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and […]

  • lexicon

Deal supported by Xplico

November, 2014|0 Comments

Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate

  • dicerna

Deal supported by Xplico

November, 2014|0 Comments

Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program

  • leo

Deal supported by Xplico

November, 2014|0 Comments

LEO Pharma and Japan Tobacco Enter into License Agreement for Novel JAK inhibitor Drug Candidate

  • bavarian

Deal supported by Xplico

October, 2014|0 Comments

Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola Vaccine

  • GALEN

Deal supported by Xplico

September, 2014|0 Comments

Distribution, License & Supply Agreement Announced with Medical Developments International

  • taris

Deal supported by Xplico

August, 2014|0 Comments

Allergan Acquires LiRIS®Program from TARIS Biomedical®

  • uniqure

Deal supported by Xplico

August, 2014|0 Comments

uniQure Acquires Cardiology Gene Therapy Company InoCard

  • medivir

Deal supported by Xplico

August, 2014|0 Comments

Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim

  • zealand

Deal supported by Xplico

July, 2014|0 Comments

Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines

  • leo

Deal supported by Xplico

July, 2014|0 Comments

LEO Pharma & KLOX Technologies strike global dermatology deal

  • pharmamar

Deal supported by Xplico

July, 2014|0 Comments

PharmaMar and Chugai Pharma Marketing Enter into a License and Commercialization Agreement in Europe for Aplidin®

  • pharmamar

Deal supported by Xplico

July, 2014|0 Comments

PharmaMar signs licence agreement with GP Pharm to market Politrate® in Italy for treating prostate cancer

  • immunocore

Deal supported by Xplico

June, 2014|0 Comments

Immunocore and Lilly Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies

  • tracon

Deal supported by Xplico

March, 2014|0 Comments

Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology

  • verastem

Deal supported by Xplico

February, 2014|0 Comments

Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718

  • inovio

Deal supported by Xplico

September, 2013|0 Comments

Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products

  • novavax

Deal supported by Xplico

June, 2013|0 Comments

Novavax Announces Public Offer for All Outstanding Shares of Isconova

  • 4sc

Deal supported by Xplico

February, 2013|0 Comments

4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases